Milicent Muyoma has been turned away twice from the clinic where she collects her HIV medication in Mathare, an informal ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Latonia Wilkins knows she needs to be on PrEP due to her non-monogamous lifestyle. But the 52-year-old Atlanta mother has ...

A series of orders from the Trump administration have the potential to disrupt the delivery of life-saving medications to HIV positive people. Here's what a disruption of this drug regimen would mean.

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Truvada, the first approved form of PrEP ... While PrEP protects against HIV infection, it does not prevent chlamydia, gonorrhea, syphilis, hepatitis C, or other sexually transmitted infections. These ...

Descovy and Truvada are prescription drugs used to treat and help prevent HIV. Both drugs come as oral tablets that are taken once per day. Truvada is available as a generic drug, while Descovy is ...

PreP is extremely effective at preventing HIV infection. According to the Centers for Disease Control and Prevention, PReP drugs like Truvada Descovy can reduce the risk of getting HIV by 99 percent ...

The sustainability and success of the implementation of any new prevention ... HIV-infected partners (HIV serodiscordant couples; 1000 couples) Open-label, daily oral Truvada, provided as 'bridge ...

two decades ago to discover whether Truvada—which was approved in 2004 to treat HIV—could also prevent the infection. “Today’s settlement ends this litigation and this final resolution ...

Truvada for PrEP, the name-brand version of the pill form of HIV prevention medication, was approved by the Food and Drug Administration in July 2012 for sexually active adults after having been ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy. The litigation ...